ELV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.66 | - | - |
| Q2'26 | $5.07 | $7.45 | +47.0% |
| Q1'26 | $6.29 | $12.58 | +99.9% |
| Q4'25 | $3.13 | $3.33 | +6.5% |
| Q3'25 | $4.94 | $6.03 | +22.0% |
| Q2'25 | $8.96 | $8.84 | -1.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $49.7B | - | - |
| Q2'26 | $49.2B | $49.8B | +1.3% |
| Q1'26 | $48.0B | $49.5B | +3.2% |
| Q4'25 | $50.3B | $49.3B | -2.0% |
| Q3'25 | - | $50.1B | - |
| Q2'25 | - | $49.4B | - |
Market Data
ELV Stock Snapshot
ELV is currently trading at $395.00, giving Elevance Health, Inc. a market cap of 84.11B and a P/E ratio of 16.9. Today's range spans $387.31–$395.70, with shares opening at $390.39 and moving up $0.86 (0.2%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 70/100.
Over the past year ELV has traded between $274.84 and $436.24 - the current price is +43.7% off the 52-week low and -9.5% from the high.
Cross-asset context supports the bullish read on ELV: when Healthcare sector conditions are favorable, large-cap names with 91/100 technical scores (BUY) and bullish sentiment (70/100) outperform on a risk-adjusted basis. Price: $395.00 (in the upper portion of its 52-week range). (P/E: 16.9) The 52-week context of $274.84–$436.24 shows the full trading history - and the current setup is one of the stronger entries within that range. At 84.11B in market cap, position sizing is the key variable, not the direction.
What makes ELV's BUY setup (91/100) particularly actionable at 84.11B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $395.00 (in the upper portion of its 52-week range in $274.84–$436.24), with sentiment running bullish at 70/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: Elevance Health, Inc. (ELV)
Elevance Health, Inc. (ELV) is a significant player in the U.S. health benefits landscape, offering a comprehensive suite of health plans and services. The company operates across four distinct segments, catering to a wide spectrum of customers including individuals, employer groups, and government-sponsored programs like Medicare and Medicaid. Its strategic focus extends beyond traditional insurance to encompass integrated offerings such as pharmacy services, specialty insurance, and advanced care management solutions.
The company's operational framework is supported by its HealthOS platform, facilitating the delivery of services under well-recognized brands like Anthem Blue Cross and Blue Shield. Elevance Health's business model is designed to provide end-to-end healthcare solutions, aiming to improve health outcomes and manage costs for its members. This integrated approach positions the company to navigate the complex dynamics of the healthcare industry by offering both payer and provider-adjacent services.
Recent performance metrics reveal a mixed earnings picture, with EPS estimates generally being surpassed while revenue figures have shown some variability against expectations. Despite these fluctuations, Elevance Health has a history of revenue growth, underscoring its market presence. Key developments include a substantial network participation agreement with Myomo, potentially expanding coverage for its innovative orthotic devices, alongside a price target adjustment from Wolfe Research.
Market Reach
Elevance Health serves a broad customer base encompassing individuals, employers, and government programs like Medicare and Medicaid.
Its diverse health plans and services are delivered under prominent brands such as Anthem Blue Cross and Blue Shield.
A recent agreement with Myomo could significantly expand its covered lives by an additional 45 million members.
Diversified Offerings
The company's value proposition extends beyond traditional health insurance to include pharmacy services and specialty offerings.
Integrated care management, virtual care, and data analytics are key components of its service suite.
The HealthOS platform underpins the delivery of these comprehensive healthcare solutions.
Regulatory Scrutiny
Elevance Health faces regulatory headwinds concerning its Medicare Advantage plans from the CMS.
Potential sanctions include a suspension of new enrollments due to past noncompliance issues.
Resolution of these CMS regulatory issues will be critical for future growth and stability.
Earnings Trends
Recent quarterly results show a tendency to exceed Earnings Per Share (EPS) estimates.
Revenue figures have demonstrated some variability against analyst expectations in recent periods.
Historical revenue growth indicates a strong market position, though detailed year-over-year trends require further data.
Valuation & Outlook
The stock currently trades at a Price-to-Earnings (P/E) ratio of approximately 10.94, suggesting a potentially attractive valuation.
The 52-week trading range indicates significant price volatility, with a high of $458.75 and a low of $273.71.
Analyst sentiment, as indicated by a price target adjustment from Wolfe Research, suggests a cautious but potentially optimistic outlook.
Positioning ELV
Elevance Health's stock presents a valuation opportunity given its P/E ratio and market position, but faces headwinds from regulatory scrutiny. Investors should consider adding to positions on signs of resolution with CMS and continued expansion of its diversified service offerings. Conversely, significant negative developments regarding Medicare Advantage compliance or a deterioration in earnings trends could warrant a reduction in exposure.
ELV Recent Earnings History
- Q4 2025
EPS: $3.33 actual vs $3.13 estimate (beat) · Revenue: $49,311M actual vs $50,315M estimate
- Q3 2025
EPS: $6.03 actual vs $4.94 estimate (beat) · Revenue: $50,087M actual
- Q2 2025
EPS: $8.84 actual vs $8.96 estimate (miss) · Revenue: $49,421M actual
- Q1 2025
EPS: $11.97 actual vs $11.48 estimate (beat) · Revenue: $48,765M actual
- Q4 2024
EPS: $3.84 actual vs $3.85 estimate (miss) · Revenue: $44,989M actual
Risk Factors
Elevance Health faces risks primarily from regulatory scrutiny and operational execution within its diverse health plan offerings. Changes in government policy or the ability to effectively manage its large member base can significantly impact financial performance.
- CMS Sanctions
The Centers for Medicare & Medicaid Services (CMS) has raised concerns regarding Elevance Health's Medicare Advantage plans. Potential sanctions, including a suspension of new enrollments, could directly reduce revenue and profitability. This risk materializes if Elevance fails to address compliance issues to CMS's satisfaction.
- Revenue Misses
Elevance has recently missed revenue expectations, indicating potential challenges in sales execution or market demand. Consistent revenue shortfalls could signal underlying issues with member acquisition or retention. This risk is present when quarterly results fall short of analyst projections.
- Network Expansion
While a contract with Myomo offers potential for expanded reach, the success of this partnership is not guaranteed. Any delays or underperformance in integrating and leveraging this new network could limit its positive impact. This risk becomes relevant if the anticipated member growth from the Myomo agreement does not materialize.
- Guidance Cuts
Analyst price target reductions, such as the one from Wolfe Research, can signal concerns about future growth or profitability. If Elevance's performance or outlook deteriorates, further downward revisions to financial guidance could occur. This risk is heightened if the company's upcoming earnings reports or management commentary are negative.
What Moves ELV Stock?
Elevance Health's stock performance is primarily driven by its ability to navigate regulatory environments and expand its service offerings through strategic partnerships.
CMS Scrutiny
Elevance Health faces potential sanctions from the Centers for Medicare & Medicaid Services (CMS) regarding its Medicare Advantage plans. This scrutiny stems from past noncompliance issues, raising concerns about enrollment restrictions.
Any negative regulatory action, such as a suspension of new enrollments, could significantly impact premium revenue and future growth prospects, leading to downward pressure on the stock price.
Myomo Partnership
A recent network participation agreement with Myomo aims to expand access to Myomo's orthotic devices across Elevance's commercial, Medicare Advantage, and Medicaid plans. This collaboration could significantly increase the covered lives for Myomo's products.
Successful integration and uptake of this partnership could drive incremental revenue and demonstrate Elevance's commitment to innovative healthcare solutions, potentially boosting investor confidence and stock valuation.
Analyst Downgrades
Recent analyst actions, such as Wolfe Research lowering its price target for Elevance Health, reflect concerns about the company's near-term outlook. These adjustments often consider factors like regulatory risks and competitive pressures.
A reduced price target signals a less optimistic view from Wall Street, which can influence investor sentiment and contribute to short-term stock price declines as the market recalibrates its expectations.
Key insight: Regulatory compliance and strategic growth initiatives are the key determinants of Elevance Health's stock trajectory. Investors are closely monitoring CMS actions and the success of new partnerships to gauge future performance.
Analyst Price Targets for ELV
The current spread of analyst price targets and ratings for Elevance Health, Inc. (ELV).
Reflects the most recently tracked analyst ratings for ELV and may lag real-time updates. Not a recommendation to buy or sell.
Key Metrics for ELV
Elevance Health's performance hinges on its ability to manage medical costs and expand its membership across diverse health plans. Investors should monitor key operational and financial indicators to gauge the company's growth trajectory and profitability.
Medical Loss Ratio: This ratio indicates the percentage of premiums spent on medical claims and quality improvements. A declining MLR suggests improved profitability for Elevance Health; a rising MLR signals pressure on margins. This is crucial as it directly impacts the company's underwriting profit and overall financial health.
Membership Growth: Measures the net increase or decrease in covered lives across Elevance Health's various plans (Commercial, Medicare, Medicaid). Consistent membership growth is a positive sign of market penetration and demand; stagnation or decline indicates competitive challenges. This metric is vital for assessing Elevance Health's top-line growth potential.
Adjusted EBITDA Margin: This metric reflects Elevance Health's operational profitability before interest, taxes, depreciation, and amortization. Expanding margins indicate efficient cost management and pricing power; contracting margins suggest rising operational expenses or pricing pressures. It's a key indicator of Elevance Health's ability to generate cash from its core operations.
Days Claims Payable: Represents the average number of days it takes for Elevance Health to pay its medical claims. A stable or slightly increasing DCP can indicate efficient working capital management; a sharp increase might signal cash flow issues or delayed payments. This is important for understanding Elevance Health's cash conversion cycle and operational efficiency.
Government Business Growth: Tracks the revenue and membership expansion within Elevance Health's Medicare and Medicaid segments. Strong growth here is positive, reflecting success in securing government contracts and serving vulnerable populations; weakness suggests challenges in these highly regulated markets. This is critical given the significant contribution of government programs to Elevance Health's overall business.
ELV Competitive Positioning
Elevance Health, Inc. (ELV) is tracked alongside these names in Healthcare Plans on DailyIQ.
Frequently Asked Questions About ELV
Is Elevance Health (ELV) stock a good investment?
Elevance Health's investment appeal hinges on its diversified health benefits offerings and expanding services beyond traditional insurance. The company's strategy to integrate pharmacy, care management, and virtual care through its HealthOS platform aims to create a more holistic healthcare experience. Investors may consider its ability to navigate regulatory environments and capitalize on growth opportunities in government and commercial markets.
What drives Elevance Health (ELV) stock price?
The stock price of Elevance Health is primarily influenced by its membership growth across its various health plans, including commercial, Medicare, and Medicaid. Profitability is also a key driver, impacted by medical cost ratios, administrative efficiency, and the success of its integrated offerings like pharmacy benefit management and care services. Regulatory developments and broader healthcare policy changes can also significantly affect investor sentiment and the company's outlook.
Does Elevance Health (ELV) pay a dividend?
Yes, Elevance Health typically pays a quarterly dividend to its shareholders. The company has a history of returning capital to investors through dividends and share repurchases. Investors should review the latest dividend declarations and the company's capital allocation strategy for current details on dividend payments and buyback programs.
What are the risks of investing in Elevance Health (ELV)?
Key risks for Elevance Health include regulatory scrutiny and potential changes in government healthcare programs like Medicare and Medicaid, which form a substantial part of its business. Competitive pressures within the health insurance market and the ability to manage healthcare costs effectively are also significant factors. Furthermore, the integration of new services and technologies presents operational challenges and execution risks.
How does Elevance Health (ELV) generate revenue?
Elevance Health generates revenue primarily through premiums collected for its health insurance plans offered to individuals, employers, and government entities. Additional revenue streams come from its pharmacy benefit management services, specialty insurance products, and a growing suite of healthcare services, including care management and data analytics, delivered through its Carelon segment.
What is Elevance Health's (ELV) strategy for growth?
The company's growth strategy focuses on expanding its membership base across all segments, particularly in government-backed programs. Elevance Health also aims to deepen customer relationships by offering a more integrated suite of healthcare services, including pharmacy, care management, and digital health solutions, to improve health outcomes and control costs. Strategic partnerships and acquisitions also play a role in its expansion efforts.
How is Elevance Health (ELV) performing financially?
Recent financial reports for Elevance Health show a mixed performance, with some quarters exceeding earnings per share estimates while missing revenue targets. The company's ability to manage medical costs and grow its high-margin service businesses are crucial for its financial health. Investors should monitor its earnings calls for updates on membership trends, cost management, and the outlook for its various business segments.
What is the valuation of Elevance Health (ELV) stock?
Elevance Health's valuation can be assessed using metrics such as its price-to-earnings (P/E) ratio, which currently stands around 10.94. Comparing this to industry peers and its historical P/E range provides context for whether the stock is considered overvalued or undervalued. Future growth prospects, profitability trends, and the company's ability to execute its strategic initiatives will influence its future valuation.
What is the outlook for Elevance Health's (ELV) Medicare Advantage business?
The outlook for Elevance Health's Medicare Advantage business is subject to regulatory changes and competitive dynamics. While the segment represents a significant portion of its revenue, recent regulatory headwinds from CMS require careful monitoring. The company's ability to ensure compliance and adapt to evolving program rules will be critical for sustained success in this market.
How does the Myomo partnership affect Elevance Health (ELV)?
The recent network participation agreement with Myomo could expand Elevance Health's reach for Myomo's assistive robotic devices, potentially adding 45 million covered lives. This partnership aligns with Elevance's strategy of broadening its service offerings and improving patient access to specialized care solutions. Its success will depend on member adoption and the integration of these services into Elevance's broader care management framework.
Learn More
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).